Author

Javier Gisbert

EFFECTIVENESS OF HELICOBACTER PYLORI TREATMENTS ACCORDING TO ANTIBIOTIC RESISTANCE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF HELICOBACTER PYLORI TREATMENTS ACCORDING TO ANTIBIOTIC RESISTANCE: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Javier Gisbert  et al.

BISMUTH QUADRUPLE REGIMEN WITH TETRACYCLINE OR DOXYCYCLINE VERSUS PYLERA® AS THIRD-LINE RESCUE THERAPY FOR H. PYLORI INFECTION: A PROSPECTIVE MULTICENTER ANALYSIS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE REGIMEN WITH TETRACYCLINE OR DOXYCYCLINE VERSUS PYLERA® AS THIRD-LINE RESCUE THERAPY FOR H. PYLORI INFECTION: A PROSPECTIVE MULTICENTER ANALYSIS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 3,439 PATIENTS
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 3,439 PATIENTS

Javier Gisbert  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

Javier Gisbert  et al.

EFFECTIVENESS OF TREATMENTS AGAINST HELICOBACTER PYLORI ACCORDING TO RESISTANCE TO CLARITHROMYCIN: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF TREATMENTS AGAINST HELICOBACTER PYLORI ACCORDING TO RESISTANCE TO CLARITHROMYCIN: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

IMPACT OF HELICOBACTER PYLORI CLARITHROMYCIN RESISTANCE ON THE TREATMENT EFFECTIVENESS: DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
IMPACT OF HELICOBACTER PYLORI CLARITHROMYCIN RESISTANCE ON THE TREATMENT EFFECTIVENESS: DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

HELICOBACTER PYLORI ANTIBIOTIC RESISTANCE: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
HELICOBACTER PYLORI ANTIBIOTIC RESISTANCE: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAïVE PATIENTS IN THE PERIOD 2013-2019: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ANTIBIOTIC RESISTANCE TRENDS OF HELICOBACTER PYLORI NAïVE PATIENTS IN THE PERIOD 2013-2019: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

Javier Gisbert  et al.

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY

Javier Gisbert  et al.

FIRST-LINE H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 24,882 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
FIRST-LINE H. PYLORI ERADICATION THERAPY IN EUROPE: RESULTS FROM 24,882 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

DIFFERENCES OF HELICOBACTER PYLORI DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
DIFFERENCES OF HELICOBACTER PYLORI DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU
MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU

Javier Gisbert  et al.

IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY
IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY

Javier Gisbert  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)

Javier Gisbert  et al.

REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY
REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY

Javier Gisbert  et al.

COMPARISON OF THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION REGIMENS BETWEEN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
COMPARISON OF THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION REGIMENS BETWEEN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

ROLE OF PROTON PUMP INHIBITORS DOSAGE IN THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF PROTON PUMP INHIBITORS DOSAGE IN THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS DURING THE PERIOD 2013-2022: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
CLINICAL PHENOTYPES THROUGH MACHINE LEARNING OF FIRST-LINE TREATED PATIENTS DURING THE PERIOD 2013-2022: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Javier Gisbert  et al.

Item 61 - 80 / 107
1 2 3
4
5 6